A network meta-analysis of the PD(L)-1 inhibitors in the salvage treatment of urothelial bladder cancer

被引：12

作者：

El Rassy, Elie ^{[1
]}

Bakouny, Ziad ^{[1
]}

Aoun, Fouad ^{[2
]}

Haddad, Fadi G. ^{[3
]}

Sleilaty, Ghassan ^{[3
]}

Assi, Tarek ^{[1
]}

Kattan, Joseph ^{[1
]}

机构：

[1] St Joseph Univ, Hotel Dieu France Univ Hosp, Fac Med, Dept Med Oncol, Beirut, Lebanon

[2] St Joseph Univ, Hotel Dieu France Univ Hosp, Fac Med, Dept Urol, Beirut, Lebanon

[3] St Joseph Univ, Fac Med, Dept Biostat, Beirut, Lebanon

来源：

IMMUNOTHERAPY | 2018年 / 10卷 / 08期

关键词：

atezolizumab; PD-1; inhibitor; PDL-1; pembrolizumab; urothelial bladder cancer; TRANSITIONAL-CELL CARCINOMA; PHASE-III TRIAL; 2ND-LINE THERAPY; CHEMOTHERAPY; GEMCITABINE; REGIMEN; IMMUNOTHERAPY; UPDATE;

D O I：

10.2217/imt-2017-0190

中图分类号：

R392 [医学免疫学]; Q939.91 [免疫学];

学科分类号：

100102 ;

摘要：

Aim: To determine which of the approved immune checkpoint inhibitors is the optimal treatment in metastatic urothelial bladder cancer. Methods & materials: Only the pivotal Phase III trials of secondline metastatic urothelial bladder cancer were included in this network meta-analysis. Results: This NMA included three pooled trials (NCT00315237, NCT02256436 and NCT02302807) of 1125 participants. Pem-brolizumab was the only treatment with positive effect on overall survival compared with the best supportive care. The treatment discontinuation rates due to adverse events of the pembrolizumab and atezolizumab did not differ from that of the best supportive care. C onclusion: Our results confirmed the superiority of pembrolizumab in the management of metastatic urothelial bladder cancer.

引用

页码：657 / 663

页数：7

共 23 条

[21] Nivolumab monotherapy in recurrent metastatic urothelial carcinoma (CheckMate 032): a multicentre, open-label, two-stage, multi-arm, phase 1/2 trial
Sharma, Padmanee
Callahan, Margaret K.
Bono, Petri
Kim, Joseph
Spiliopoulou, Pavlina
Calvo, Emiliano
Pillai, Rathi N.
Ott, Patrick A.
de Braud, Filippo
Morse, Michael
Le, Dung T.
Jaeger, Dirk
Chan, Emily
Harbison, Chris
Lin, Chen-Sheng
Tschaika, Marina
Azrilevich, Alex
Rosenberg, Jonathan E.
[J]. LANCET ONCOLOGY, 2016, 17 (11) : 1590 - 1598
[22] Eastern cooperative oncology group phase II trial of ifosfamide in the treatment of previously treated advanced urothelial carcinoma
Witte, RS
Elson, P
Bone, B
Knop, R
Richardson, RR
Dreicer, R
Loehrer, PJ
[J]. JOURNAL OF CLINICAL ONCOLOGY, 1997, 15 (02) : 589 - 593
[23] Yafi FA, 2011, CURR ONCOL, V18, pE25

← 1 2 3 →